MIR6887: A Potential Drug Target and Biomarker for Cancer (G102466205)
MIR6887: A Potential Drug Target and Biomarker for Cancer
MIR6887 (hsa-miR-6887-3p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and its functions continue to be a subject of debate in the scientific community.
MIR6887 is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. It is expressed in a variety of tissues and cells and can interact with various protein molecules to regulate their stability and translation efficiency. One of the most interesting features of MIR6887 is its unique structure, which is composed of a long stem-loop and a short terminal extension.
The stem-loop region of MIR6887 is composed of three exons that are closely spaced and conserved across different species. The first exon codes for a protein known as hsa-miR-6887-long, which contains the majority of the stem-loop sequence. The second exon codes for a protein known as hsa-miR-6887-short, which contains a variable region that includes a binding site for a protein known asBeclin1 (Beclin1-AS). The third exon codes for a protein known as hsa-miR-6887- ZERO, which contains a variable region that includes a binding site for a protein known asP180 (P180-AS).
The terminal extension of MIR6887 is composed of a single exon that codes for a protein known as hsa-miR-6887- TER, which contains a variable region that includes a binding site for a protein known asTrpm2 (Trpm2-AS).
MIR6887 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and metabolism. It has been shown to regulate the stability and translation efficiency of various proteins, including the cell signaling pathway known as the NF-kappa pathway. NF-kappa is a well-known protein that plays a crucial role in cell growth, apoptosis, and development, and it is a target of many drugs that are used to treat various diseases.
One of the most interesting aspects of MIR6887 is its potential as a drug target. Its unique structure and expression pattern make it an attractive target for researchers to study, and its functions continue to be a subject of debate in the scientific community.
Some researchers have suggested that MIR6887 may be a potential drug target for cancer because it has been shown to play a role in various cellular processes that are involved in cancer development, including cell growth, apoptosis, and metabolism. It has also been shown to interact with various proteins that are involved in the NF-kappa pathway, which is a well-known protein that plays a crucial role in cancer development.
Others have suggested that MIR6887 may be a potential biomarker for cancer because it has been shown to be expressed in various types of cancer cells, including breast, lung, and ovarian cancer cells. Its unique expression pattern and stability make it an attractive target for researchers to study, and its functions as a biomarker may have implications for the early detection and diagnosis of cancer.
In conclusion, MIR6887 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern make it an attractive target for researchers to study, and its functions continue to be a subject of debate in the scientific community. Further research is needed to fully understand the role of MIR6887 in
Protein Name: MicroRNA 6887
The "MIR6887 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR6887 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR6888 | MIR6889 | MIR6890 | MIR6891 | MIR6892 | MIR6893 | MIR6894 | MIR6895 | MIR7-1 | MIR7-2 | MIR7-3 | MIR7-3HG | MIR708 | MIR7106 | MIR7107 | MIR7108 | MIR7109 | MIR711 | MIR7110 | MIR7111 | MIR7112 | MIR7113 | MIR7114 | MIR7150 | MIR7151 | MIR7152 | MIR7153 | MIR7154 | MIR7155 | MIR7156 | MIR7158 | MIR7159 | MIR7160 | MIR7161 | MIR7162 | MIR718 | MIR720 | MIR744 | MIR7515 | MIR758 | MIR759 | MIR760 | MIR761 | MIR762 | MIR762HG | MIR764 | MIR765 | MIR766 | MIR767 | MIR769 | MIR770 | MIR7702 | MIR7703 | MIR7704 | MIR7705 | MIR7706 | MIR7843 | MIR7844 | MIR7845 | MIR7846 | MIR7847 | MIR7848 | MIR7849 | MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975 | MIR7976 | MIR7977 | MIR802 | MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874
